Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director · Executive Chair | July 17, 2026 | August 11, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date July 17, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,261 |
Ending reported balance
After 2026-08-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-17 · Exercise / conversion · Acquired 1 · Balance 1 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Row 2 · 2026-08-06 · Exercise / conversion · Acquired 1,666 · Balance 1,667 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Row 3 · 2026-08-06 · Tax withholding · Disposed 406 · Balance 1,261 F2: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-17 · Exercise / conversion · Disposed 1 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3: On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-06 · Exercise / conversion · Disposed 1,666 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F4: On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs.
F3: On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.
F4: On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,839 |
Reported balance
After 2026-04-30 transaction · row 1
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 113,839 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CoLucid Pharmaceuticals, Inc.
Report date March 01, 2017 · Filed March 01, 2017
Section 16 reporting ended · disclosed 2017-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2025-07-09 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-01 · Disposition to issuer · Disposed 6,577 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-01 · Disposition to issuer · Disposed 997 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.24 · Expires 2026-05-10 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-01 · Disposition to issuer · Disposed 8,897 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-07-01 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-01 · Disposition to issuer · Disposed 1,630 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.20 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-01 · Disposition to issuer · Disposed 453 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 11, 2026 01:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-343070 · ownership.xml · derivative · entry 5 White Marvin L · CIK 0001493324 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F4 · derivative.exercise_date: On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant. F4 · derivative.expiration_date: On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 01:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 406 | $4.07 | $1,652.42 |
DisclosureSEC source: 0001193125-26-343070 · ownership.xml · nonDerivative · entry 3 White Marvin L · CIK 0001493324 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,261 F2 · kind: Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 01:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-343070 · ownership.xml · nonDerivative · entry 2 White Marvin L · CIK 0001493324 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| July 17, 2026 Filed Aug 11, 2026 01:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-343070 · ownership.xml · derivative · entry 4 White Marvin L · CIK 0001493324 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. F3 · derivative.expiration_date: On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. Read SEC document |
| July 17, 2026 Filed Aug 11, 2026 01:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-343070 · ownership.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 11,296 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001493324-26-000002 · wk-form4_1777930151.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,296 Underlying: Common Stock · 11,296 shares Expires 2033-04-30 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 25,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001493324-26-000002 · wk-form4_1777930151.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,839 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:31 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-105922 · ownership.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 10 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-097269 · ownership.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20 Underlying: Common Stock · 30 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On July 17, 2024, the reporting person was granted 22,325 (30 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. F2 · derivative.expiration_date: On July 17, 2024, the reporting person was granted 22,325 (30 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 10 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-097269 · ownership.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 15,824 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001367644-25-000110 · wk-form4_1746232287.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 Underlying: Common Stock · 15,824 shares Expires 2032-04-29 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 34,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000110 · wk-form4_1746232287.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,495 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 6 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032187 · ownership.xml · derivative · entry 4 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 28,750 (18 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. F3 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 28,750 (18 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 6 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-032187 · ownership.xml · nonDerivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 21:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032187 · ownership.xml · derivative · entry 3 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8 Underlying: Common Stock · 8 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 38,750 (24 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. F2 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 38,750 (24 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 21:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 8 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-032187 · ownership.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 14,287 | $11.97 | $171,015.39 |
DisclosureSEC source: 0001367644-24-000184 · wk-form4_1731531882.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,092 F1 · price: On November 11, 2024, Mr. White sold an aggregate of 14,287 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $11.84 - $12.11. The Company maintains a record of the transactions and copies will be provided upon request. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 20:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 22,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-084950 · ownership.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,325 Underlying: Common Stock · 22,325 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on June 17, 2025. F2 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on June 17, 2025. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:40 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001367644-24-000086 · wk-form4_1716946839.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:40 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000086 · wk-form4_1716946839.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,379 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 9,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025878 · ownership.xml · derivative · entry 4 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,584 Underlying: Common Stock · 9,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. F3 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 9,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025878 · ownership.xml · nonDerivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 21:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 12,917 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025878 · ownership.xml · derivative · entry 3 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,833 Underlying: Common Stock · 12,917 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 38,750 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. F2 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 38,750 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 21:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 12,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025878 · ownership.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| January 28, 2024 Filed Jan 30, 2024 23:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009002 · ownership.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 28, 2022. F2 · derivative.expiration_date: On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 28, 2022. Read SEC document |
| January 28, 2024 Filed Jan 30, 2024 23:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 4,792 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-009002 · ownership.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| May 25, 2023 Filed May 30, 2023 23:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 33,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000109 · wk-form4_1685488148.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,949 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 38,750 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-23-016774 · doc4.xml · derivative · entry 4 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,750 Underlying: Common Stock · 38,750 shares Expires 2033-03-02 F4 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 38,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016774 · doc4.xml · derivative · entry 3 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,750 Underlying: Common Stock · 38,750 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on March 2, 2024. F3 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 9,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016774 · doc4.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,168 Underlying: Common Stock · 9,582 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. F2 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 9,582 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016774 · doc4.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| January 29, 2023 Filed Jan 30, 2023 18:07 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 4,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005423 · doc4.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,792 Underlying: Common Stock · 4,791 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. F2 · derivative.expiration_date: On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2023 Filed Jan 30, 2023 18:07 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 4,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-005423 · doc4.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 21:23 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 28,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034873 · doc4.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 28,750 shares Expires not disclosed F1 · security: As previously disclosed in a Form 4 filed on March 4, 2022, the reporting person was granted 28,750 options on such date. At the time of the grant, there were insufficient shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan to make the full grant of equity award to the reporting person that was approved for issuance by Aptevo Therapeutics Inc.'s Compensation Committee. As such, the equity award was split into two separate grants with the first portion of 28,750 options granted on March 4, 2022 and the second portion of 28,750 restricted stock units granted on June 7, 2022, following stockholder approval of an increase in shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (as Amended and Restated). F2 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: The RSU vests in three approximately equal annual installments beginning on March 3, 2023. F3 · derivative.expiration_date: The RSU vests in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000091 · wf-form4_165402831199670.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,102 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| March 04, 2022 Filed Mar 4, 2022 23:13 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 28,750 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001209191-22-016457 · doc4.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 28,750 shares Expires 2032-03-03 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 23:01 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-22-000114 · white.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,583 Underlying: Common Stock · 4,792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. F2 · derivative.expiration_date: On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 23:01 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 4,792 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-22-000114 · white.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000087 · wf-form4_162189005445348.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,656 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| January 29, 2021 Filed Feb 18, 2021 02:03 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 14,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000147 · white.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,375 Underlying: Common Stock · 14,375 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. F3 · derivative.expiration_date: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2021 Filed Feb 18, 2021 02:03 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 43,125 | $0.00 Strike: $33.50 | $0.00 |
DisclosureSEC source: 0001019056-21-000147 · white.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,125 Underlying: Common Stock · 43,125 shares Expires 2031-01-29 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000151 · wf-form4_160193327342258.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,629 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service on the Board of Directors. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 4,813 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 8 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,813 Underlying: Common Stock · 4,813 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F10 · derivative.exercise_date: These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 16,625 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 7 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,625 Underlying: Common Stock · 16,625 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F9 · derivative.exercise_date: These options vest in full on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 10,828 | Not disclosed Strike: $21.28 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 6 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,828 shares Expires 2029-02-28 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F8 · derivative.exercise_date: This stock option award provides for vesting in three approximately equal annual installments beginning on February 28, 2020. Prior to July 27, 2020, all but 7,219 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 10,828 | Not disclosed Strike: $43.82 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 5 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,828 shares Expires 2028-03-09 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F7 · derivative.exercise_date: This stock option award provides for vesting in three approximately equal annual installments beginning on March 9, 2019. Prior to July 27, 2020, all but 3,609 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 5,414 | Not disclosed Strike: $30.10 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 4 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,414 shares Expires 2027-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F6 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on June 1, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 5,414 | Not disclosed Strike: $27.44 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 3 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,414 shares Expires 2027-02-24 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F5 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on February 24, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 14,319 | Not disclosed Strike: $41.16 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 2 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,319 shares Expires 2026-08-03 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F4 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on August 3, 2019. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,545 | Not disclosed Strike: $25.20 | Not disclosed |
DisclosureSEC source: 0001019056-20-000441 · white.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,545 shares Expires 2021-05-22 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F2 · derivative.exercise_date: The stock option award vested on May 22, 2017. This award was originally part of a grant from Emergent BioSolutions Inc. ("Emergent") dated May 22, 2014 of which two-thirds were vested at the time of conversion to issuer's equity pool. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.